Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence

Sequence-dependent synergistic effect of aumolertinib-pemetrexed combined therapy on EGFR-mutant non-small-cell lung carcinoma with pre-clinical and clinical evidence

Background: Inevitably developed resistance of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) limited its clinical benefit on non-small cell lung cancer (NSCLC). Upfront combination therapy is promising to prevent this resistance. Compelling clinical ev...

Full description

Bibliographic Details
Main Authors: Ao, L. (Author), Cui, J. (Author), Fang, S. (Author), Gao, Y. (Author), Jia, W. (Author), Liu, J. (Author), Shan, Y. (Author), Wang, G. (Author), Zhang, J. (Author), Zhang, K. (Author), Zhou, F. (Author)
Format: Article
Language:English
Published: BioMed Central Ltd 2022
Subjects:
acrylamide derivative
Acrylamides
aumolertinib
Aumolertinib
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Chromatography, Liquid
EGFR protein, human
epidermal growth factor receptor
Epidermal growth factor receptor
ErbB Receptors
genetics
human
Humans
indole derivative
Indoles
liquid chromatography
Lung Neoplasms
lung tumor
metabolism
non small cell lung cancer
Non-small cell lung cancer
pathology
pemetrexed
Pemetrexed
protein kinase inhibitor
Protein Kinase Inhibitors
pyrimidine derivative
Pyrimidines
Retrospective Studies
retrospective study
Sequential drug administration
Synergistic effect
tandem mass spectrometry
Tandem Mass Spectrometry
tumor cell line
Vascular Endothelial Growth Factor A
vasculotropin A
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items